BridgeBio Reports Results From Phase 1/2 Trial Of Investigational Gene Therapy For Congenital Adrenal Hyperplasia; Says Increase In Endogenous Cortisol Production Achieved In All Patients In Higher Dose Cohorts Of BBP-631
Portfolio Pulse from Benzinga Newsdesk
BridgeBio announced results from its Phase 1/2 trial of the investigational gene therapy BBP-631 for Congenital Adrenal Hyperplasia. The trial showed increased cortisol production in higher dose cohorts, with mild to moderate adverse events. However, the results did not justify further capital investment, leading to a $50M budget reduction for gene therapy.
September 10, 2024 | 8:49 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
BridgeBio's trial of BBP-631 showed positive results in cortisol production but did not meet investment criteria, leading to a $50M budget cut in gene therapy.
The trial results were positive in terms of cortisol production but not sufficient to justify further investment, leading to a significant budget cut. This could negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100